Novo Nordisk is a global pharmaceutical company founded in Denmark in 1923 and the world’s leader in the development and manufacture of drugs for the treatment of diabetes and obesity. Today, the company operates via 80 branches around the world, and its products are supplied to more than 170 countries.  

In 2015, Novo Nordisk opened a plant in Kaluga Region in Russia.  

The plant produces a full range of advanced insulins in compliance with all GMP standards, corporate standards of the company, and the Russian legislation on pharmaceutical manufacturing. The enterprise applies advanced solutions in energy efficiency and environmental protection. More than RUB 10 billion has been invested in the development of production in Kaluga Region with more than 300 jobs created and a total production area of 13,000 m2. 

Novo Nordisk is committed to improving the availability of advanced medicines aimed at controlling socially significant diseases. In July 2021, the company began the first stage of localisation of the new-generation insulin Fiasp® at its plant in Kaluga Region. The launch took place in a challenging epidemiological context. However, the company believes that, despite the coronavirus pandemic, the manufacture of advanced insulins should develop. 

The first stage of production involves assembling, packaging, labelling and releasing FlexPen® pre-filled injection pens. Simultaneously, preparations are in progress for the localisation of the 2nd stage, which involves manufacturing a finished dosage form using the original substance from Denmark, which will begin by 2023. 

Novo Nordisk supports the VI All-Russian GMP Conference with International Participation and is ready to share its experience in localising production, as well as best practices for product quality and safety assurance.  

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *

Заполните поле
Заполните поле
Пожалуйста, введите корректный адрес email.
Вы должны согласиться с условиями для продолжения